1. Hims & Hers Health stock dropped 25% after the FDA announced the end of the semaglutide shortage; 2. Hims plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide and tirzepatide; 3. Despite the setback, Hims shows strong financial health with 77% Y/Y revenue growth and no long-term debt.